Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAL: Intranasal Abuse Potential of ADAIR
NCT04647903Phase 1Completed
- Sponsor
- GRI Bio, Inc.
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salmeterol + fluticasone in attention deficit hyperactivity disorder (ADHD) and narcolepsy (4 arms), sponsored by GRI Bio, Inc. Primary endpoint: Maximum Drug Liking at 24 hours. Started Oct 2020; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
attention deficit hyperactivity disorder (ADHD)narcolepsy
Beyond the preview
Go deeper on NCT04647903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647903.